Search results for "Prognostic factor"

showing 10 items of 94 documents

Classical pediatric Hodgkin lymphoma in very young patients: the Italian experience

2019

Many studies have reported a more favorable outcome in younger patients with Hodgkin lymphoma (HL). The aims of this study were to find an appropriate age cutoff able to identify low-risk children and to describe the natural history of 135 very young patients affected by classic HL (cHL). The best age cutoff was identified at 7 years of age. EFS (p = .0451) and PFS (p = .00921) were significantly better in the group of younger patients. The OS rate at 10 years was 97.0% in the younger group and 92.5% in the older one (p = .0448). However, age was not found to be an independent prognostic factor in multivariate analysis and the better prognosis in younger patients seems to be related to more…

MaleCancer Researchmedicine.medical_specialtyPrognostic factorMultivariate analysisAdolescent03 medical and health sciences0302 clinical medicineInternal medicineOutcome Assessment Health CaremedicineCutoffHumansPublic Health SurveillanceFavorable outcomeAge of OnsetChildchemotherapeutic approachesbusiness.industryAge FactorsDisease ManagementInfantHematologyPrognosisHodgkin DiseaseSurvival AnalysisNatural historypediatricOncologyItalyROC CurveSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA030220 oncology & carcinogenesisChild PreschoolLymphoma and Hodgkin diseaseHodgkin lymphomaDisease characteristicsFemalebusiness030215 immunology
researchProduct

Factors that predict response of patients with hepatitis C virus infection to boceprevir

2012

Background & Aims Little is known about factors associated with a sustained virologic response (SVR) among patients with hepatitis C virus (HCV) infection to treatment with protease inhibitors. Methods Previously untreated patients (from the Serine Protease Inhibitor Therapy 2 [SPRINT-2] trial) and those who did not respond to prior therapy (from the Retreatment with HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2 [RESPOND-2] trial) received either a combination of peginterferon and ribavirin for 48 weeks or boceprevir, peginterferon, and ribavirin (triple therapy) after 4 weeks of peginterferon and ribavirin (total treatment duration, 28–48 wk). A good response to interfer…

MaleCirrhosisMESH: Logistic ModelsHepacivirusMESH: Risk AssessmentGastroenterologyPolyethylene GlycolsMESH: Recombinant ProteinsMESH: Genotype0302 clinical medicineOdds RatioProspective StudiesMESH: Treatment OutcomeResponse to Therapy0303 health sciencesMESH: Polymorphism Single NucleotideGastroenterologyvirus diseases3. Good healthMESH: RNA ViralHCVDrug Therapy Combination030211 gastroenterology & hepatologyClinical Trial; Genetic; Prognostic Factors; Response to Therapy; Adult; Antiviral Agents; Biomarkers; Canada; Drug Therapy Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interleukins; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism Single Nucleotide; Proline; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States; Viral Load; GastroenterologyViral loadmedicine.medical_specialtyMESH: InterleukinsGenotypeProlineInterferon alpha-2MESH: PhenotypeAntiviral AgentsRisk Assessment03 medical and health sciencesDrug TherapyGeneticMESH: RibavirinMESH: CanadaBoceprevirHumansPolymorphismMESH: ProlineMESH: HumansPrognostic FactorsInterleukinsMESH: AdultOdds ratiomedicine.diseaseUnited Statesdigestive system diseasesClinical trialLogistic ModelschemistryImmunologyMESH: FemaleBiomarkersTime Factorsmedicine.disease_causechemistry.chemical_compoundRisk FactorsInterferonMESH: Risk FactorsMESH: HepacivirusViralSingle NucleotideViral LoadHepatitis CClinical TrialRecombinant ProteinsEuropePhenotypeTreatment OutcomeCombinationRNA ViralFemaleMESH: Interferon-alphaMESH: Viral Loadmedicine.drugAdultMESH: Antiviral AgentsCanadaHepatitis C virusPolymorphism Single NucleotideMESH: Multivariate AnalysisInternal medicineRibavirinmedicineMESH: United States030304 developmental biologyMESH: Hepatitis CHepatologybusiness.industryRibavirinMESH: Time FactorsMESH: Biological MarkersInterferon-alpha[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Prospective StudiesMESH: MaleMESH: Odds RatioMESH: Drug Therapy CombinationMESH: Polyethylene GlycolsMultivariate AnalysisRNAInterferonsMESH: Europebusiness
researchProduct

Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study

2015

Background: The clinical course of advanced adrenocortical carcinoma (ACC) is heterogeneous. Our study aimed primarily to refine and make headway in the prognostic stratification of advanced ACC.Patients and methods: Patients with advanced ENSAT ACC (stage III or stage IV) at diagnosis registered between 2000 and 2009 in the ENSAT database were enrolled. The primary end point was overall survival (OS). Parameters of potential prognostic relevance were selected. Univariate and multivariate analyses were carried out: model 1 'before surgery'; model 2 'post-surgery'.Results: Four hundred and forty-four patients with advanced ENSAT ACC (stage III: 210; stage IV: 234) were analyzed. After a medi…

MaleLung NeoplasmsENSATGastroenterologyPROPOSALClinical endpointAdrenocortical carcinomaENDOCRINEStage (cooking)Liver NeoplasmsIntraventricular blockHematologyMiddle AgedSERIESCANCEREuropeSurvival RateOncologymedicine.veinLymphatic MetastasisSURVIVALFemalemedicine.medical_specialtyUNITED-STATESBone NeoplasmsInferior vena cavaInternal medicineGRASmedicineadrenocortical carcinomaPrognostic factors adrenocortical carcinomaHumansNeoplasm InvasivenessSurvival rateAdrenocortical carcinoma; ENSAT; GRAS; Prognostic factors; Oncology; HematologyNeoplasm StagingRetrospective Studiesbusiness.industryCancerprognostic factorsRetrospective cohort studymedicine.diseaseAdrenal Cortex NeoplasmsSurgeryAdrenocortical carcinoma prognosisprognosisNeoplasm GradingNeoplasm Recurrence LocalbusinessFollow-Up StudiesAnnals of Oncology
researchProduct

Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: The outcome of incomplete resections

2013

The type of surgery (radical pleurectomy (RP) vs. extrapleural pneumonectomy (EPP)) remains controversial for malignant pleural mesothelioma (MPM). Macroscopic complete resection (MCR) is a key prognostic factor. It is unclear, if patients undergoing incomplete RP within a standardized multimodality treatment protocols have any advantage in terms of survival and if EPP could theoretically have avoided incomplete resections (R2).Eighty-eight patients underwent RP followed by chemoradiation from 2002 to 2011 within a prospective multimodality treatment study at a single institution. MCR were compared to R2 within this patient cohort retrospectively. EPP eligibility was assessed retrospectivel…

MaleMesotheliomaPulmonary and Respiratory MedicineExtrapleural PneumonectomyCancer Researchmedicine.medical_specialtyPrognostic factorLung NeoplasmsPleural NeoplasmsKaplan-Meier EstimateDisease-Free SurvivalmedicineHumansProspective StudiesStage (cooking)PneumonectomyAgedRetrospective StudiesProportional hazards modelPleural mesotheliomabusiness.industryMultimodality TreatmentMesothelioma MalignantChemoradiotherapyThoracic Surgical ProceduresCombined Modality TherapySurvival AnalysisSurgeryTreatment OutcomeOncologyCohortFemalebusinessPleurectomyhormones hormone substitutes and hormone antagonistsLung Cancer
researchProduct

Health-related quality of life is a prognostic factor for survival in older patients after colorectal cancer diagnosis: A population-based study

2015

International audience; Background: Studies carried out in the context of clinical trials have shown a relationship between survival and health-related quality of life in colorectal cancer patients.Aims: We assessed the prognostic value of health-related quality of life at diagnosis and of its longitudinal evolution on survival in older colorectal cancer patients. Methods: All patients aged >= 65 years, diagnosed with new colorectal cancer between 2003 and 2005 and registered in the Digestive Cancer Registry of Burgundy were eligible. Patients were asked to complete the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 at inclusion, three, six …

MaleMultivariate analysisColorectal cancerAppetiteDefinitions0302 clinical medicineQuality of lifeSurveys and QuestionnairesCancer registries030212 general & internal medicineAged 80 and overRelative survivalHazard ratioGastroenterologyScoresPrognosis3. Good healthSurvival RateOncology030220 oncology & carcinogenesisColonic NeoplasmsFemalePerspectivesmedicine.medical_specialtyPredict survivalClinical-TrialsContext (language use)Prognostic factorsFeeding and Eating DisordersAssociation03 medical and health sciencesInternal medicinePatient report outcomemedicineHumansMortalitySurvival rateAgedHepatologyRectal Neoplasmsbusiness.industryElderly-patientsCancer[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaseElderly patientsQuality of LifePhysical therapyEuropean-organizationbusinessFollow-Up StudiesDigestive and Liver Disease
researchProduct

Analysis of risk and prognostic factors in a population of pediatric patients hospitalized for acute malnutrition at the Chiulo hospital, Angola

2021

Abstract Background Malnutrition is a multifactorial pathology in which genetic, epigenetic, cultural, environmental, socio-economic factors interact with each other. The impact that this disease has on the health of children worldwide is dramatic. Severe acute malnutrition in particular is a disease affecting nearly 20 million preschool children worldwide, most of them in Africa and South East Asia. Objectives This work aims to investigate potential prognostic factors in the clinical evolution of acute malnutrition and potential risk factors for the development of the disease. Methods Our study was carried out at the “Hospital da Missão Catolica do Chiulo”, in Angola, where the NGO Doctors…

MaleNutrition EducationPopulationSevere Acute MalnutritionBreastfeedingBreastfeedingDiseasePrognostic factorsChild Nutrition DisordersPediatricsRJ1-570Environmental healthHumansMedicineeducationWastingPrognostic factorFamily Characteristicseducation.field_of_studyFamily unitSub-Saharan Africabusiness.industryWasting.ResearchBody WeightInfantPrognosismedicine.diseaseBody HeightWastingHospitalizationMalnutritionAngolaRisk factorsFood SecuritySevere acute malnutritionChild PreschoolFemaleRisk factormedicine.symptombusinessItalian Journal of Pediatrics
researchProduct

The prognostic value of biological markers in paediatric Hodgkin lymphoma

2015

Abstract Background Many biological and inflammatory markers have been proposed as having a prognostic value at diagnosis of Hodgkin lymphoma (HL), but very few have been validated in paediatric patients. We explored the significance of these markers in a large population of 769 affected children. Patients and methods By using the database of patients enrolled in A.I.E.O.P. (Associazione Italiana di Emato-Oncologia Pediatrica) trial LH2004 for paediatric HL, we identified 769 consecutive patients treated with curative intent from 1st June 2004 to 1st April 2014 with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), or hybrid COPP/ABV (cyclophosphamide, vincristine, prednisone, pr…

MaleOncologyCancer ResearchPathologyTime FactorsDatabases Factualmedicine.medical_treatmenthodgkin lymphoma; paediatric; prognostic factorHodgkin lymphoma; Paediatric; Prognostic factor; Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers Tumor; Child; Child Preschool; Databases Factual; Disease Progression; Disease-Free Survival; Female; Ferritins; Hodgkin Disease; Humans; Infant; Infant Newborn; Italy; Kaplan-Meier Estimate; Leukocyte Count; Male; Multivariate Analysis; Neoplasm Staging; Platelet Count; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Blood Platelets; EosinophilsKaplan-Meier EstimateProcarbazineLeukocyte Countchemistry.chemical_compound0302 clinical medicineRisk FactorsPrednisoneAntineoplastic Combined Chemotherapy ProtocolsChildPrognostic factorTumorAge FactorsHodgkin DiseaseVinblastineTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyOncologyPaediatricChild Preschool030220 oncology & carcinogenesisDisease ProgressionFemalemedicine.drugBlood Plateletsmedicine.medical_specialtyVincristineAdolescentDacarbazineBleomycinDisease-Free SurvivalDatabases03 medical and health sciencesPredictive Value of TestsInternal medicineBiomarkers TumormedicineHumansPreschoolFactualNeoplasm StagingProportional Hazards ModelsRetrospective StudiesChemotherapyPlatelet Countbusiness.industryInfant NewbornInfantNewbornEosinophilschemistryABVDFerritinsMultivariate AnalysisbusinessBiomarkersHodgkin lymphoma030215 immunologyEuropean Journal of Cancer
researchProduct

Pain intensity as prognostic factor in cancer pain management

2015

Aim The aim of this study was to prospectively assess the prognostic value of initial pain intensity and its duration in advanced cancer patients. Methods A prospective study was conducted in a sample of patients with cancer requiring pain control. Patients underwent standard analgesic strategies used in our palliative care units. Pain intensity was measured at admission (T0) and after successful dose titration or opioid/route switching within a week (Ts). Patients were also asked about their pain intensity reported 15 days before admission (T-15). Doses of opioids and duration of opioid use were recorded. Patients were also assessed for the presence of incident pain, neuropathic pain, alco…

MalePalliative careSettore MED/42 - Igiene Generale E ApplicataSeverity of Illness IndexPain assessmentNeoplasms80 and overProspective StudiesCancer painProspective cohort studyCancerPain MeasurementAged 80 and overPrognostic factorAnalgesicsPalliative CareAssessment tools; Cancer; Cancer pain; Opioid; Opioid analgesics; Opioid response; Pain assessment; Pain intensity; Pain measurement; Prognostic factors; Aged; Aged 80 and over; Analgesics; Analgesics Opioid; Female; Humans; Logistic Models; Male; Middle Aged; Neoplasms; Neuralgia; Pain; Pain Management; Pain Measurement; Palliative Care; Prognosis; Prospective Studies; Stress Psychological; Treatment Outcome; Severity of Illness Index; Anesthesiology and Pain MedicineAssessment toolMiddle AgedPrognosisAnalgesics OpioidAssessment toolsTreatment OutcomeAnesthesiaNeuropathic painFemalemedicine.drugOpioid responsePain assessmentAnalgesicPainOpioidPain intensityPrognostic factorsStressOpioid analgesicAssessment tools; Cancer; Cancer pain; Opioid; Opioid analgesics; Opioid response; Pain assessment; Pain intensity; Pain measurement; Prognostic factors; Anesthesiology and Pain MedicinemedicineHumansPain ManagementAdverse effectAgedbusiness.industryAnesthesiology and Pain MedicineLogistic ModelsOpioidOpioid analgesicsPsychologicalNeuralgiaCancer painbusinessStress Psychological
researchProduct

The Duke treadmill score with bicycle ergometer: Exercise capacity is the most important predictor of cardiovascular mortality

2018

Background The Duke treadmill score, a widely used treadmill testing tool, is a weighted index combining exercise time or capacity, maximum ST-segment deviation and exercise-induced angina. No previous studies have investigated whether the Duke treadmill score and its individual components based on bicycle exercise testing predict cardiovascular death. Design Two populations with a standard bicycle testing were used: 3936 patients referred for exercise testing (2371 men, age 56 ± 13 years) from the Finnish Cardiovascular Study (FINCAVAS) and a population-based sample of 2683 men (age 53 ± 5.1 years) from the Kuopio Ischaemic Heart Disease study (KIHD). Methods Cox regression was applied for…

MaleTime FactorsEpidemiologyDuke treadmill score030204 cardiovascular system & hematologyFull Research PaperAngina0302 clinical medicineRisk Factorscardiovascular mortalityCause of DeathMedicine030212 general & internal medicineSegment deviationta315FinlandExercise ToleranceSisätaudit - Internal medicineta3141Exercise capacityTreadmill testingMiddle AgedPrognosisfyysinen kuntoCardiorespiratory FitnessCardiovascular DiseasesCardiologyBody Compositionstress testFemaleBicycle ergometerCardiology and Cardiovascular MedicineRisk PredictionAdultkuolleisuusmedicine.medical_specialtyBiolääketieteet - BiomedicinekuntotestitRisk Assessment03 medical and health sciencesPredictive Value of TestsInternal medicineHumansCardiovascular mortalityAgedbusiness.industryprognostic factorsennusteet217 Medical engineeringmedicine.diseaseBicyclingPhysical Fitness3121 General medicine internal medicine and other clinical medicineExercise Testsydän- ja verisuonitauditStock price indexbusiness
researchProduct

Recurrence of esophageal cancer after R0 surgery: risk factors and evolution

2013

Introduction despite advances in surgical and adjuvant therapy, recurrence in esophageal cancer submitted to R0 surgery remains high. The aim is to define risk factors and recurrence patterns. Additionally, to show the management carried out and the outcome of patients showing recurrence. Material and methods observational and prospective study that included 61 patients. Neoadjuvancy therapy was indicated on T3, T4 and N+ tumors and every lymph node dissection was performed in two fields. Recurrence is defined at distance, regional or local, when, recurrence is detected after six months. According to clinical features and the recurrences, a palliative, chemotherapeutic or surgical managemen…

Malemedicine.medical_specialtyEsophageal NeoplasmsEsophageal cancerRecurrenciaCurative esophagectomyPrognostic factorsRecurrenceRisk FactorsAdjuvant therapymedicineHumansProspective StudiesStage (cooking)Risk factorlcsh:RC799-869Prospective cohort studyLymph nodeCáncer de esófagobusiness.industryEsofaguectomía curativaGastroenterologyGeneral MedicineMiddle AgedEsophageal cancermedicine.diseaseSurgeryDissectionTreatment Outcomemedicine.anatomical_structureFemalelcsh:Diseases of the digestive system. GastroenterologyLymphNeoplasm Recurrence LocalbusinessFactores pronósticoRevista Espanola de Enfermedades Digestivas
researchProduct